Novavax’s deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under ...

Novavax's combo and standalone flu shots triggered a 2.4–5.7x rise in immune response over baseline in seniors. Over 98% of adverse events were mild or moderate in Novavax's Phase 3 trial of ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in adults aged 65 and older, similar to already approved shots against ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

The hold comes after “the identification of a safety signal of decreases in CD4+T-cell (CD4) and absolute lymphocyte counts in a subset of participants receiving the combination of GS-1720 and ...

Key Takeaways. Moderna's combo shot for flu and COVID-19 showed strong antibody responses. The U.S. Food and Drug Administration wants more proof that it protects against sickness and not just ...

The next-gen shot showed a 9.3% higher relative vaccine efficacy in participants 12 and older, Moderna said. The number was higher, 13.5%, in a descriptive sub-group analysis of trial participants ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

Novavax's stand-alone trivalent flu and dual Covid-19-influenza vaccines had similar immune responses to those seen in other licensed brands, according to phase 3 trial data. The Gaithersburg, Md ...